Pretreatment p53 Nuclear Overexpression as a Prognostic Marker in Superficial Bladder Cancer Treated with Bacillus Calmette–Guérin (BCG)

Saint, F.; Belda, Marie-Aude Le Frère; Quintela, Rodrigo; Hoznek, Andràs; Patard, Jean‐Jacques; Bellot, J; Popov, Z̆.; Zafrani, Élie Serge; Abbou, Claude C.; Chopin, Dominique; Medina, Sixtina Gil Diez de

doi:10.1016/j.eururo.2003.11.018

Cited by 47 publications

(24 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies included moderate intensity for the calculated p53 expression, which differed distinctly from our results. The report of Saint et al [17], using only strong intensity, was similar to our method and revealed similar results for the prognostic value of p53 overexpression. …”

Section: Discussionsupporting

confidence: 69%

“…Numerous studies have defined p53 overexpression in bladder cancer as nuclear immunostaining extent with a cutoff value of 20% [9,12,16,17]. Others have used various cutoff values to define overexpression, including 10% [13], 15% [19] or 35% [20 ](table 3).…”

Section: Discussionmentioning

confidence: 99%

“…Several researchers have investigated the effectiveness of p53 expression for patients with NMIBC who underwent intravesical BCG treatment after initial TURB [9,10,11,12,13,14,16,17,18]. The correlation between p53 status and BCG therapy for NMIBC is still debatable (table 3) [9,10,11,12,13,16,17].…”

Section: Discussionmentioning

confidence: 99%

“…Saint et al [17] analyzed 102 patients who were treated with BCG and stated that p53 overexpression is an independent predictor of recurrence. In that series, p53 nuclear overexpression in NMIBC was also associated with a high risk of disease progression, cancer-related death and a shortened time to recurrence.…”

Section: Discussionmentioning

confidence: 99%

“…The correlation between p53 status and BCG therapy for NMIBC is still debatable (table 3) [9,10,11,12,13,16,17]. …”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

A Six-Week Course of Bacillus Calmette-Guérin Prophylaxis Is Insufficient to Prevent Tumor Recurrence in Nonmuscle Invasive Bladder Cancer with Strong-Positive Expression of p53

Choi

et al. 2010

Oncology

View full text Add to dashboard Cite

Objective: To determine the impact of p53 overexpression on tumor recurrence after bacillus Calmette-Guérin (BCG) intravesical therapy in patients with nonmuscle invasive bladder cancer (NMIBC). Methods: Between January 1999 and December 2008, 275 patients who received six BCG intravesical instillations for NMIBC (transitional cell carcinoma) after transurethral resection were assessed for differences in outcomes according to the level of p53 overexpression. A multivariate logistic regression model was applied to assess the predictive capacity of variables for recurrence. Overexpression of p53 was determined using monoclonal p53-DO7 antibody. Results: In 275 subjects, the recurrence rate was higher based on the level of p53 expression (p = 0.019). Based on multivariate analysis, a strong-positive p53 >60% (p = 0.031) and tumor grade (p = 0.015) were significant predictors for recurrence. Patients with a strong-positive p53 >60% had a much lower 5-year biochemical recurrence-free survival rate than patients with p53 ≤60% (72.1 vs. 31.5%, p < 0.001). Conclusions: Strong overexpression of p53 was predictive of recurrence in patients with NMIBC undergoing intravesical BCG treatment. A 6-week induction course of BCG alone is not sufficient to prevent recurrence in patients with NMIBC with high p53 expression; additional prophylactic strategies are needed for these patients.

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…The correlation between p53 status and BCG therapy for NMIBC is still debatable (table 3) [9,10,11,12,13,16,17]. …”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

A Six-Week Course of Bacillus Calmette-Guérin Prophylaxis Is Insufficient to Prevent Tumor Recurrence in Nonmuscle Invasive Bladder Cancer with Strong-Positive Expression of p53

Choi

et al. 2010

Oncology

View full text Add to dashboard Cite

show abstract

Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon‐alpha

Esuvaranathan

Chiong

Thamboo

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUNDNuclear p53 and retinoblastoma protein (pRb) were reported to be poor prognostic indicators for transitional cell carcinoma of the bladder. The authors sought to determine the prognostic value of nuclear p53 and pRb in superficial bladder transitional cell carcinoma patients who were treated with intravesical bacille Calmette‐Guerin (BCG) or BCG with interferon‐alpha (IFN‐α).METHODSA prospective histological review was performed for 80 superficial bladder transitional cell carcinoma patients who underwent postresection intravesical regimes of BCG (81mg, n = 33 or 27 mg, n = 20) or BCG (27 mg) with IFN‐α (n = 27), and followed for a mean of 4.5 years. Hematoxylin and eosin (H & E) and immunoperoxidase staining were performed on tissue sections. Nuclear p53 and pRb immunoreactivity were assessed semiquantitatively, by using a combination of staining extent and intensity, to categorize overexpression or underexpression. Data were analyzed by using chi‐square analysis, multiple logistic regression, and Kaplan‐Meier curves.RESULTSpRb expression was not associated with patient outcome after BCG‐alone therapy, but pRb underexpression was significantly associated with BCG nonresponse and tumor recurrence (P = .047) after BCG and IFN‐α (BCG + IFN‐α) therapy. Low‐grade tumors were associated with pRb overexpression, with or without nuclear p53 underexpression (P = .019; P = .043, respectively). p53 expression alone or in combination with pRb expression had no significant relation with tumor response to BCG alone or BCG + IFN‐α with respect to recurrence, progression, or cancer‐specific death.CONCLUSIONSNuclear pRb underexpression may be predictive of nonresponse and cancer recurrence after intravesical BCG + IFN‐α therapy. Nuclear p53 expression or its combination with pRb expression is not associated with post‐BCG clinical outcome, so p53 expression or p53 with pRb expression should not be used to influence decisions concerning BCG‐alone or BCG + IFN‐α therapy. Cancer 2007. © 2007 American Cancer Society.

show abstract

The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta‐analysis

Liao

Tang

Wang

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Bladder cancer is one of the most common urological cancers all over the world, and NMIBC occupies almost 80% of recently diagnosed bladder cancer cases. Progress and recurrence of bladder cancer are the main problems during the disease. The level of TP53 mutation is obviously higher in the high stage than the lower. This meta‐analysis is to evaluate the potential diagnosis feature of TP53 mutation by the expression of TP53 mutation of Ta stage vs high stage in bladder cancer. Methods A systematic search of databases was conducted, and some relevant articles were selected. Next, the meta‐analysis was carried out according to the standard guidelines. Results There were seven researches in which 677 participants were selected at the basis of inclusion standard. TP53 mutation was associated highly with increased diagnosis of bladder cancer. We found that the high stage of bladder cancer has obviously higher level of TP53 mutation than the lower stage, and these patients of MIBC have higher expression of TP53 mutation compared with NMIBC. No significant publication bias has been observed in this meta‐analysis. The expression of TP53 mutation might be a diagnose‐related biomarker for lots of patients with bladder cancer. Conclusions The results of this meta‐analysis provided further evidences that the expression of TP53 mutation was associated with the diagnosis efficiency of advanced bladder cancer. Higher expression of TP53 mutation was observed in the high stage of bladder cancer or the MIBC, and lower expression of TP53 mutation in the Ta stage of bladder cancer or the NMIBC. The expression level of TP53 mutation was probably a critical diagnosed biomarker in advanced bladder cancer.

show abstract

Pretreatment p53 Nuclear Overexpression as a Prognostic Marker in Superficial Bladder Cancer Treated with Bacillus Calmette–Guérin (BCG)

Cited by 47 publications

References 32 publications

A Six-Week Course of Bacillus Calmette-Guérin Prophylaxis Is Insufficient to Prevent Tumor Recurrence in Nonmuscle Invasive Bladder Cancer with Strong-Positive Expression of p53

A Six-Week Course of Bacillus Calmette-Guérin Prophylaxis Is Insufficient to Prevent Tumor Recurrence in Nonmuscle Invasive Bladder Cancer with Strong-Positive Expression of p53

Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon‐alpha

The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta‐analysis

Contact Info

Product

Resources

About